Amendments to the claims

This listing of the claims replaces all other listings of the claims pending in the present application. Please amend claim 37 as follows:

1. (previously presented) A compound of the formula:



or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein:

X is CR^{14};

R^1 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9;

R^2 is H;

A represents an alkyl chain of 1,2, or 3 carbon atoms which is optionally mono- or di-substituted at each carbon with substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, and C_1-C_6 alkyl-NR^8R^9, or

A and B jointly form a C_3-C_6 carbocycle, optionally substituted at each atom with R^7;

B represents an alkyl chain of 1,2 or 3 carbons atoms, which is optionally mono- or di-substituted at each carbon with substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, and C_1-C_6 alkyl-NR^8R^9, or

B and R^6 jointly form a C_3-C_6 aminocarbocycle, which is optionally substituted at each atom with R^7;

R^3 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7, C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9;

R^4 is selected from aryl or heteroaryl, each of which is substituted with 1 to 5 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, C_1-C_6 alkyl-OR^7, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, C_1-C_6 alkyl-$CONR^8R^9$, $COOR^7$, C_1-C_6 alkyl-$COOR^7$, CN, C_1-C_6 alkyl-CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted;

R^5 is selected from:

C_1-C_6 alkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from halo, C_1-C_2 haloalkyl, oxo, OR^7, cyano, NR^8R^9, $CONR^8R^9$, $COOR^7$, $SO_2NR^8R^9$, SO_2R^7, $NR^{11}COR^{12}$, $NR^{11}SO_2R^7$;

Aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl(C_5-C_8)cycloalkyl, or heteroaryl(C_5-C_8)cycloalkyl, each of which is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be take together to form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

C_3-C_{10} cycloalkyl or C_2-C_9 heterocycloalkyl containing one, two, or three O, S, or N atoms, each of which is optionally substituted with 1 to 6 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, oxo, halogen, C_1-C_6 haloalkyl, OR^7, NR^8R^9, (with the proviso that when two OR^7 or NR^8R^9 substituents are geminally located on the same carbon R^7 is not H and the geminally located OR^7 or NR^8R^9 substitutuents can be taken together to form a C_2-C_4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, oxo, hydroximino, C_1-C_6 alkoximino, $SO_2NR^8R^9$, SO_2R^7, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$,

$COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be taken together to form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring; or

3- or 4-piperidinyl, 3-pyrrolidinyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydrothiopyranyl, 3- or 4-(1,1-dioxo) tetrahydrothiopyranyl, 1-azabicyclo[4.4.0]decyl, 8-azabicyclo[3.2.1]octanyl, norbornyl, quinuclidinyl, indolin-2-one-3-yl, 2-(methoximino)-perhydroazepin-6-yl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from R^7, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, CN, $COOR^7$ $SO_2NR^8R^9$, and SO_2R^7;

R^6 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl each of which is optionally substituted with 1 to 5 substituents independently from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, and SO_2R^7;

R^7 is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^{13}$, CN, $SO_2NR^8R^9$, and SO_2R^{13}, with the proviso that when R^7 is SO_2R^{13}, R^{13} cannot be H;

R^8 and R^9 are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_6 alkynyl, heterocycloalkyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl, or

R^8 and R^9, taken together, can form a C_3-C_6 aminocarbocycle or a C_2-C_5 aminoheterocycle each of which is optionally substituted with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl;

R^{11} is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl;

R^{12} is selected from H, aryl, heteroaryl, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, optionally substituted with OR^7, NR^8R^9, C_3-C_6 aminocarbocycle, or C_2-C_5 aminoheterocycle;

R^{13} is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, with the proviso that when R^7 is SO_2R^{13}, R^{13} cannot be H; and

R^{14} is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, or CN; and wherein

R^5 is phenyl, naphthyl, 2-,3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, triazinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5-oxazolyl, isoxazolyl, indolyl, pyrazolyl, quinolyl, isoquinolyl, 2-, 4-, or 5-thiazolyl, benzothiadiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4-triazolyl, 2-triazinyl, 2-pyrazinyl, 2-, or 3-furanyl, 2-, or 3-thienyl, 2-, or 3-benzothienyl, or 1-, 2- or 5-tetrazolyl each of which is optionally substituted with 1 to 5 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, triflurometh ylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein 2 adjacent substituents may be taken together to form a cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring.

2. (canceled)

3-6. (canceled)

7. (original) A compound according to claim 1, wherein;

X is CH,

R^1 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl; and

R^6 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl.

8. (original) A compound according to claim 1, wherein:

X is CH;

R^1 is C_1-C_6 alkyl;

R^2 is H or C_1-C_6 alkyl;

R^3 is C_1-C_6 alkyl, trifluoromethyl, or C_1-C_6alkyl-O C_1-C_6alkyl; and

R^6 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl.

9. (original) A compound according to claim 1, wherein;

X is CH;

R^1 is C_1-C_6 alkyl;

R^2 is H or C_1-C_6 alkyl;

R^3 is C_1-C_6 alkyl, trifluoromethyl, or C_1-C_6alkyl-O C_1-C_6alkyl;

R^4 is phenyl, mono, di, or trisubstituted with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl,

(C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, C_1-C_6 alkyl-OR^7, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, C_1-C_6 alkyl-$CONR^8R^9$, $COOR^7$, C_1-C_6 alkyl-$COOR^7$, CN, C_1-C_6 alkyl-CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted,

R^6 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl; and

R^7, R^8, and R^9 are as defined in claim 1.

10. (original) A compound according to claim 1, wherein:

X is CH;

R^1 is C_1-C_6 alkyl;

R^2 is H or C_1-C_6 alkyl;

R^3 is C_1-C_6 alkyl, trifluoromethyl, or C_1-C_6alkyl-O C_1-C_6alkyl;

R^4 is phenyl, mono, di, or trisubstituted with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, C_1-C_6 alkyl-OR^7, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, C_1-C_6 alkyl-$CONR^8R^9$, $COOR^7$, C_1-C_6 alkyl-$COOR^7$, CN, C_1-C_6 alkyl-CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted,

R^5 is

C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from halo, C_1-C_2 haloalkyl, OR^7, cyano, NR^8R^9, $CONR^8R^9$, $COOR^7$, $SO_2NR^8R^9$, SO_2R^7, $NR^{11}COR^{12}$, $NR^{11}SO_2R^7$; or

3- or 4-piperidinyl, 3-pyrrolidinyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4- tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydrothiopyranyl, 3- or 4-(1,1-dioxo) tetrahydrothiopyranyl, 1-azabicyclo[4.4.0]decyl, 8-azabicyclo[3.2.1]octanyl, norbornyl, quinuclidinyl, indolin-2-one-3-yl, 2-(methoximino)-perhydroazepin-6-yl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from R^7, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, CN, $COOR^7$ $SO_2NR^8R^9$, and SO_2R^7;

R^6 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl; and

R^7, R^8, R^9, R^{11}, and R^{12} are as defined in claim 1.

11. (original) A method for treating eating disorders and cardiovascular disorders comprising administering to a patient suffering from an eating disorder or cardiovascular disorder a compound according to claim 1.

12. (original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

13-17. (canceled)

18. (original) A compound according to any one of claim I wherein in an assay of NPY binding the compound exhibits an K_i of 1 micromolar or less.

19. (original) A compound according to any one of claim 1 wherein in an assay of NPY binding the compound exhibits an K_i of 100 nanomolar or less.

20. (original) A compound according to any one of claim 1 wherein in an assay of NPY binding the compound exhibits an K_i of 100 nanomolar 10 nanomolar or less.

21. (original) A method for treating obesity or bulimia nervosa which comprises administering an effective amount of a compound according to claim 1 to a patient in need thereof.

22. (original) A method for treating hypertension which comprises administering an effective amount of a compound according to claim 1 to a patient in need thereof.

23. (previously presented) A compound in accordance with formula I



wherein:

X is CR^{14};

R^1 is selected from H, C_1-C_6 alkyl, C_3-C_6 ycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9;

R^2 is H;

A is $(CH_2)_m$, where m is 1,2 or 3 and is optionally mono- or di-substituted on each occurrence with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, or A and B jointly form a C_3-C_6 carbocycle, optionally substituted at each occurrence with R^7;

B is $(CH_2)_n$, where n is 1,2 or 3 and is optionally mono- or di-substituted on each occurrence with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR7; C_1-C_6 cyanoalkyl, NR^8R^9, and C_1-C_6 alkyl-NR^8R^9;

or, as mentioned above, B and A jointly form a C_3-C_6 carbocycle, optionally substituted at each occurrence with R^7;

R^3 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 akynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7, C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9;

R^4 is selected from aryl or heteroaryl, each of which is substituted with 1 to 5 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, C_1-C_6 alkyl-OR^7, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, C_1-C_6 alkyl-$CONR^8R^9$, $COOR^7$, C_1-C_6 alkyl-$COOR^7$, CN, C_1-C_6 alkyl-CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted;

R^5 is selected from:

C_1-C_6 alkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from halo, C_1-C_2 haloalkyl, oxo, OR^7, cyano, NR^8R^9, $CONR^8R^9$, $COOR^7$, $SO_2NR^8R^9$, SO_2R^7, $NR^{11}CO\,R^{12}$, $N\,R^{11}SO_2R^7$;

Aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl(C_5-C_8)cycloalkyl, or heteroaryl(C_5-C_8)cycloalkyl, where aryl is phenyl or naphthyl, and heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4-, or 5-pyrimimidinyl, triazinyl, 1-, 2-, or 4-imidazolyl 2-, 4-, or 5-oxazolyl, isoxazolyl indolyl, pyrazolyl, quinolyl, isoquinolyl, 2-, 4-, or 5-thiazolyl, benzothiadiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4-triazolyl, 2-triazinyl, 2-pyrazinyl, 2-, or 3-furanyl, 2-, or 3-thienyl, 2-, or 3-benzothienyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10}

cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluoromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR7, C_1-C_6 alkyl- NR^8R^9, $CONR^8R^9$, COOR7, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be take together to form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

C_3-C_{10} cycloalkyl optionally substituted with 1 to 6 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, oxo, halogen, C_1-C_6 haloalkyl, OR^7, NR^8R^9, (with the proviso that when two OR^7 or NR^8R^9 substituents are geminally located on the same carbon R^7 is not H and the geminally located OR^7 or NR^8R^9 substitutuents can be taken together to form a C_2-C_4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl- NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, oxo, is hydroximino, C_1-C_6 alkoximino, $SO_2NR^8R^9$, SO_2R^7, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be taken together to

form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring; or

3- or 4-piperidinyl, 3-pyrrolidinyl, 3- or 4-tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydropyranyl, 3-tetrahydrofuranyl, 3- or 4-tetrahydrothiopyranyl, 3- or 4-(1,1-dioxo) tetrahydrothiopyranyl, 1-azabicyclo[4.4.0]decyl, 8-azabicyclo[3.2.1]octanyl, norbornyl, quinuclidinyl, indolin-2-one-3-yl, 2-(methoximino)-perhydroazepin-6-yl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from R^7, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, CN, $COOR^7$ $SO_2NR^8R^9$, and SO_2R^7;

R^6 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6) alkyl each of which is optionally substituted with 1 to 5 substituents independently from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^3, C_1-C_6 alkyl- NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, and SO_2R^7;

R^7 is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^{13}$, CN, $SO_2NR^8R^9$, and SO_2 R^{13}, with the proviso that when R^7 is SO_2 R^{13}, R^{13} cannot be H;

R^8 and R^9 are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_6 alkynyl, heterocycloalkyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl, or R^8 and R^9, taken together, can form a C_3-C_6 aminocarbocycle or a

C_2-C_5 aminoheterocycle each of which is optionally substituted with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl;

R^{11} is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl;

R^{12} is selected from H, aryl, heteroaryl, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, optionally substituted with O R^7, NR^8R^9, C_3-C_6 aminocarbocycle, or C_2-C_5 aminoheterocycle;

R^{13} is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, with the proviso that when R^7 is R^{13}, R^{13} cannot be H; and

R^{14} is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, or CN;

or a pharmaceutically acceptable salt, hydrate or prodrug thereof.

24. (previously presented) A compound in accordance with formula I



or a pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:

X is CR^{14};

R^1 is selected from H, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9;

R^2 is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl or (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, wherein each alkyl or cycloalkyl group may be optionally substituted with 1 to 3 R^{7a} groups;

R^2 may optionally join with R^5 and the two and the 2 nitrogen atoms to which they are bound to form a 6 to 10 membered heterocyclic ring optionally substituted at each carbon with $R^{7(a)}$;

A represents an alkyl chain of 1, 2 or 3 carbon atoms which is optionally mono- or di-substituted at each carbon with substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR^7; C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, or A and B jointly form a C_3-C_6 carbocycle, optionally substituted at each occurrence with R^{7a};

B represents an alkyl chain of 1,2 or 3 carbons atoms, which is optionally mono- or di-substituted at each carbon with substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR^7, C_1-C_6 alkyl-OR7; C_1-C_6 cyanoalkyl, NR^8R^9, and C_1-C_6 alkyl-NR^8R^9;

R^3 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, halo, C_1-C_6 haloalkyl, OR7, C_1-C_6 alkyl-OR^7, C_1-C_6 cyanoalkyl, NR^8R^9, C_1-C_6 allyl-NR^8R^9;

R^4 is selected from aryl or heteroaryl, each of which is substituted with 1 to 5 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, C_1-C_6 alkyl-OR^7, NR^8R^9, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, C_1-C_6 alkyl-$CONR^8R^9$, $COOR^7$, C_1-C_6 alkyl-$COOR^7$, CN, C_1-C_6 alkyl-CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl)- , C_2-C_4 alkynyl wherein at least one of the positions ortho or para to the point of attachment of the aryl or heteroaryl ring to the pyrazole is substituted;

R^5 is selected from:

C_1-C_6 alkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, each of which is substituted with 1 to 5 groups independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10}, cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6, alkenyl, halogen, C_1-C_6 haloalkyl, OR^7, NR^8R^9, (with the proviso that when two OR^7 or NR^8R^9substituents are geminally located on the same carbon R^7 is not H and the geminally located OR^7 or NR^8R^9 substitutuents can be taken together to form a C_2-C_4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl- NR^8R^9, CO NR^8R^9, $COOR^7$, CN, oxo, hydroximino, C_1-C_6 alkoximino, $SO_2NR^8R^9$, SO_2R^7, heterocycloalkyl, aryl, heteroaryl, where aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected at

each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C_3-C_{10}, cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring; with the proviso that C_1-C_6 alkyl group is substituted with a C_1-C_6 alkyl group to give a C_7-C_{10} alkyl group

Aryl(C_1-C_6) alkyl, heteroaryl(C_1-C_6)alkyl, aryl(C_5-C_8)cycloalkyl, or heteroaryl(C_5-C_8)cycloalkyl, each of which is optionally substituted with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluoromethylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), wherein any 2 adjacent substituents may be taken together to form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkenyl, or a 3 to 10 membered mono- or bicyclic heterocycle containing 1-3 O, S or N atoms, each of which is optionally substituted with 1 to 6 substituents independently selected from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, OR^7, NR^8R^9, (with the proviso that when two OR^7 or NR^8R^9 substituents are geminally located on the same carbon R^7 is not H and the geminally located OR^7 or NR^8R^9 substitutuents can be taken together to form a C_2-C_4 ketal, oxazoline, oxazolidine, imidazoline, or imidazolidine heterocycle), C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, oxo, hydroximino, C_1-C_6 alkoximino, $SO_2NR^8R^9$, SO_2R^7, COR^7, heterocycloalkyl, aryl, C_1-C_6 alkylaryl, heteroaryl, C_1-C_6 alkylheteroaryl where aryl or heteroaryl is optionally substituted

with 1 to 5 substituents independently selected at each occurrence from C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethylsulfonyl, OR7, NR^8R^9, C_1-C_6 alkyl-OR7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl), with the proviso that 2 adjacent substituents can optionally form together a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring; or

aryl or heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from halogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, halogen, C_1-C_6 haloalkyl, trifluromethiylsulfonyl, OR^7, NR^8R^9, C_1-C_6 alkyl-OR^7, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, $S0_2R^7$, aryl, heteroaryl, heterocycloalkyl, 3-, 4-, or 5-(2-oxo-1,3-oxazolidinyl)- , wherein any 2 adjacent substituents may be taken together to form a C_3-C_{10} cycloalkyl ring, a C_3-C_{10} cycloalkenyl ring or a heterocycloalkyl ring;

R^6 is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, aryl(C_1-C_6)alky- l, heteroaryl(C_1-C_6)alkyl each of which is optionally substituted with 1 to 5 substituents independently from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, and SO_2R^7;

R^7 is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl- NR^8R^9, $CONR^8R^9$, $COOR^{13}$, CN, $SO_2NR^8R^9$, and SO_2R^{13};

R^{7a} is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl each optionally substituted with 1 to 5 substituents independently selected from halogen, C_1-C_6 haloalkyl, OR^{13}, NR^8R^9, C_1-C_6 alkyl-OR^{13}, C_1-C_6 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^{13}$, CN, $SO_2NR^8R^9$, and SO_2R^{13}, with the proviso that when R^{7a} is SO_2R^{13}, R^{13} cannot be H;

R^8 and R^9 are independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_6 alkynyl, heterocycloalkyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl, or $R^8$and R^9 taken together, can form a C_3-C_6 aminocarbocycle or a C_2-C_5 aminoheterocycle each of which is optionally substituted with C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkenyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_1-C_3 haloalkyl, or heterocycloalkyl, C_1-C_8 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C_1-C_8 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_6 arylalkyl or C_1-C_6 heteroarylalkyl;

R^{11} is selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl;

R^{12} is selected from H, aryl, heteroaryl, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, optionally substituted with OR^7, NR^8R^9, C_3-C_6 aminocarbocycle, or C_2-C_5 aminoheterocycle;

R^{13} is independently selected at each occurrence from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, with the proviso that when R^7 is for SO_2 R^{13}, R^{13} cannot be H; and

R^{14} is H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, (C_3-C_{10} cycloalkyl) C_1-C_6 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, halo, or CN.

25. (original) A compound according to claim 24, wherein R^{14} is H, C_1-C_4 alkyl, F or Cl.

26. (original) A compound according to claim 25, wherein

R' is H, C_1-C_4 alkyl, (C_3-C_6 cycloalkyl) C_1-C_2 alkyl, where the alkyl and cycloalkyl groups are optionally substituted with 1-3 fluorines.

R^3 is H, C_1-C_4 alkyl, (C_3-C_6 cycloalkyl) C_1-C_2 alkyl, where the alkyl and cycloalkyl groups are optionally substituted with 1-3 fluorines.

A is CH_2, optionally substituted with one or two of the following: F, CF_3, or C_1-C_3 alkyl;

B is a 1, 2 or 3 carbon chain, optionally substituted with one or two of the following: F, CF_3, or C_1-C_3 alkyl.

27. (original) A Compound according to claim 26, wherein

R^2 is H;

R^6 is H;

R^4 is phenyl, substituted with 2 or 3 substituents independently selected from C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, C_2-C_4 alkenyl, F, Cl, CF_3, CHF_2, CH_2CF_3, OMe, OCF_3, OEt, OPr, OiPr, C_2-C_4 alkyl OH, C_2-C_6 alkynyl, wherein the phenyl ring is minimally 2,4 di-substituted.

28. (previously presented) A Compound according to claim 27, wherein

A is CH_2;

B is CH_2;

R^{7a} is independently selected at each occurrence from H, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, (C_3-C_6) C_1-C_2 alkyl, C_1-C_2 fluoroalkyl, heterocycloalkyl, C_1-C_4 alkanoyl, aroyl, heteroaroyl, aryl, heteroaryl, C_1-C_2 arylalkyl or C_1-C_2 heteroarylalkyl each optionally substituted with 1 to 3 substituents independently selected from F, Cl, CF_3, OR^{13}, NR^8R^9, C_1-C_2 alkyl-OR^{13}, C_1-C_2 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^{13}$, and CN;

R^8 is H, C_1-C_3 alkyl, CF_3 or CH_2CF_3;

R^9 is H or C_1-C_3 alkyl;

R^{13} is H, C_1-C_3 alkyl, CF_3 or $CH_2C F_3$.

29. (original) A Compound according to claim 27, wherein

A is CH_2, optionally substituted with one or two of the following: F, CF_3, or methyl, ethyl, isopropyl;

B is CH_2, optionally substituted with one or two of the following: F, CF_3, methyl, ethyl,

or Isopropyl.

30. (previously presented) A Compound according to claim 29, wherein

R^5 is C_1-C_7, alkyl, C_3-C_6 cycloalkyl, or C_3-C_6 cycloalkyl C_1-C_2 alkyl, substituted with F, CF_3, OR^7 or NR^8R^9;

A is CH_2, optionally substituted with methyl;

B is CH_2, optionally substituted with methyl;

X is CH.

31. (original) A compound according to claim 30, wherein

R^7 is H, C_1-C_3 alkyl, CF_3 or CH_2CF_3;

R^8 is H, C_1-C_3 alkyl, CF_3 or CH_2CF_3,

R^9 is H or C_1-C_3 alkyl or N R^8R^9 taken together to form a pyrrolidine, piperidine or morpholine ring.

32. (previously presented) A Compound according to claim 29, wherein

R^5 is 3- or 4-tetrahydropyranyl, 3-tetrahydrofluranyl, 3- or 4-tetrahydrothiopyranyl, 3- or 4-cyclhexenyl, or 3-cyclopentenyl, optionally substituted with 1 or 2 substituents selected from C_1-C_3 alkyl;

A is CH_2, optionally substituted with methyl;

B is CH_2 optionally substituted with methyl; and

X is CH.

33. (original) A Compound according to claim 29, wherein

R^5 is 3- or 4-piperidinyl or 3-pyrrolidinyl, optionally substituted on 1 or 2 carbons with C_1-C_3 alkyl, and one substituent on nitrogen from H, C_1-C_6, alkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, (C_3-C_6 cycloalkyl) C_1-C_2 alkyl, C_1-C_4 alkenyl, C_1-C_3 fluoroalkyl, C_2-C_4 alkyl-OR^7, C_2-C_4 alkyl-NR^8R^9, heterocycloalkyl, CO- C_1-C_4 alkyl, aryl, C_1-C_3, alkylaryl, heteroaryl, C_1-C_3 alkylheteroaryl where aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_3 alkyl, F, Cl, C_1-C_2 fluoroalkyl, OR^7, NR^8R^9, C_1-C_2 alkyl-OR^7, C_1-C_2 alkyl-NR^8R^9, $CONR^8R^9$, $COOR^7$, CN, $SO_2NR^8R^9$, SO_2R^7, aryl, heteroaryl, heterocycloalkyl, 3 -, 4-, or 5 -(2-oxo-1,3-oxazolidinyl).

34. (previously presented) A Compound according to claim 33, wherein

R^5 is 3- or 4-piperidinyl or 3-pyrrolidinyl, optionally substituted on nitrogen with H, C_1-C_3 alkyl, CH_2CF_3, acetyl, pyridyl, benzyl, methylenepyridyl, pyrimidinyl, or pyrazinyl, where the aryl or heteroaryl group is optionally substituted with 1 to 2 substituents independently selected at each occurrence from C_1-C_3, alkyl, F, Cl, CF_3, OR^7, NR^8R^9;

R^7 is H, C_1-C_2, alkyl, CF_3 or CH_2CF_3;

R^8 is H, C_1-C_2 alkyl, CF_3 or CH_2CF_3;

R^9 is H or C_1-C_2 alky;

A is CH_2, optionally substituted methyl;

B is CH_2, optionally substituted with methyl;

X is CH.

35. (original) A compound according to claim 29, wherein

R^5 is C_1-C_2 arylalkyl, C_1-C_2 heteroarylalkyl, C_3-C_4 arylcycloalkyl, or C_3-C_4 heteroarylcycloalkyl, where aryl is phenyl or naphthyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5 pyrimidinyl, triazinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5-oxazolyl, isoxazolyl, indolyl, pyrazolyl, quinolyl, isoquinolyl, 2-, 4-, or 5-thiazolyl, benzothiadiazolyl, 1-, 3- or 4 pyrazolyl, 1-, 3- or 4-triazolyl, 2-triazinyl, 2-pyr, zinyl, 2-, or 3-furanyl, 2-, or 3-thienyl, 2-, or 3-benzothienyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_1-C_3 alkyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, (C_3-C_6 cycloalkyl) C_1-C_2 alkyl, C_1-C_6 alkenyl, F, Cl, C_1-C_2 fluoroalkyl, OR^7, NR^8R^9, C_1-C_2 alkyl-OR^7, C_1-C_2 alkyl-NR^8R^9or CN.

36. (previously presented) A compound according to claim 35, wherein

R^5 is phenethyl, pyridinylethyl, or 2-tetrahydonaphthylenyl, each of which is optionally substituted with 1 to 2 substituents independently selected at each occurrence from C_1-C_2 alkyl, F, Cl, CF_3 OR^7, NR^8R^9;

R^7 is H, C_1-C_2 alkyl, CF_3 or CH_2CF_3;

R^8 is H, C_1-C_2 alkyl, CF_3 or CH_2CF_3;

R^9 is H or C_1-C_2 alkyl;

A is CH_2, optionally substituted with methyl;

B is CH_2, optionally substituted with methyl;

X is CH.

37. (currently amended) A compound according to claim ~~28~~ 1, where the structure is [3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-(6-methyl-

piperidin-2-ylmethyl)-amine.

38. (original) A compound according to claim 31, where the compound is selected from the group consisting of:

2-{2-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethylamino}-butan-1-ol;

N-{2-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a]pyrimidin-7-ylamino]-ethyl}-N'-methyl-cyclohexane-1,4-diamine;

N-{2-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethyl}-N'-ethyl-cyclohexane-1,4-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4-morpholin-4-yl-cyclohexyl)-ethane-1,2-diamine;

4-{2-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethylaminol} -cyclohexanol;

3-{2-[3-(2,6-dichloro-4-methox- y-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethylamino}-pro- pane-1,2-diol;

N-{2-[3(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethyl}-N'-isobutyl-cyclohexane-1,4-diamine;

N-{2-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[l 1,5-a]pyrimidin-7-ylamino]-ethyl}-N'-isobutyl-cyclohexane-1,4-diamine;

4-{2-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-1-methyl-ethylamino}-cyclohexanol;

2-{2-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylamino]-ethylamino}-cyclohexanol;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazo to [1,5-a]pyrimidin-7-yl]-N'-(4,4,4-trifluoro-butyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,2-trifluoro-ethyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-trifluoromethyl-cyclohexyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5 -a]pyrimidin-7-yl]-N'-(4-trifluoromethyl-cyclohexyl)-ethane 1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2-difluoro-ethyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-1-methyl-ethyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazoto [1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-cyclohexyl)-ethane-1,2-diamine.

39. (original) A compound of claim 32, where the compound is selected from the group consisting of N-[3-(2,6-dichloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-pyran-4-yl)-ethane-1,2-diamine; N-[3-(2,4-dichloro-6-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydropyran -4-yl)-ethane-1,2-diamine; N-[3-(2,6-dichlork)-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydropyran-4-yl)-ethane-1,2-diamine; N1-[3-(2,6-Dichloro-phenyl)-2,5-dimethyl-pyrazo to [1,5-a]pyrimidin-7-yl]-N2&-(tetrahydropyran -4-yl)-propane-1,2-diamine; N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N-(2-methyl-tetrahydro-ftiran-3-yl)-ethane-1,2-dia- mine; N-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyri- midin-7-yl]-N'-(tetrahydropyran -4-yl)-ethane-1,2-diamine; 3,5-dichloro-4-{2,5-dimethyl-7-[2-(tetrahydro-pyran-4-ylamino)-ethylamino-]-pyrazolo [1,5-a]pyrimidin-3-yl}-benzonitrile; N-[3-(2,6-dichloro-4-propo- xy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-pyra- n-4-yl)-ethane-1,2-diamine; 2-(3,5-dichloro-4-(2,5-dimethyl-7-[2-(tetrahyd- ro-pyran-4-ylamino)-ethylamino]-pyrazolo [1,5-a]pyrimidin-3-yl} -phenyl)-propan -2-ol; N-[3-(2,6-dichloro-4-cyclopent-1-enyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(tetrahydro-pyran-4-yl)-ethane-1- ,2-diamine; N-[8-(2,6-dichloro-4-ethoxy-phenyl)-2,7-dimethyl-pyrazolo [1,5-a] [1,3,5]triazin-4-yl]-N'-(tetrahydro-pyran-4-yl)-ethane-1,2-diamin- e; (3.5-dichloro-4-(2,5-dimethyl-7-[2-(tetrahydro-pyran-4-ylamino)-ethylam- ino]-pyrazolo[1,5-a]pyrimidin-3-yl}-phenyl)-methanol; N-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N-(2-methyl-tetrahydro-furan -3-yl)-ethane-1,2-diamine; N-[5-tert-butyl-3-(2,6-dichloro-4-methoxy-phen-

yl) -2-methyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-pyran-4-yl)-e- thane-1,2-diamine; N-[3-(2,6-dichloro-4-ethoxy-phenyl)-5-ethyl-2-methyl-py- razolo[1,5-a]pyrimidin-7-yl]-N-(tetrahydro-pyran-4-yl)-ethane-1,2-diamine; N-cyclohex-3-enyl-N'-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyra- zolo[1,5-a]pyrimidin-7-yl]-ethane -1,2-diamine; N-cyclohex-3-enyl-N'-[8-(2- ,6-dichloro-4-ethoxy-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-- yl]-ethane-1,2-diamine; N-cyclopent-3-enyl-N'-[3-(2,6-dichloro-4-methoxy-p- henyl)-2,5 -dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-ethane-1,2-diamine.

40. (Previously presented) A compound of claim 34 where the structure is selected from the group consisting of

N-[3-(2,6-dichloro-phenyl)-2,5-dimethyi-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-19 piperidin-4-yl-ethane-1,2-diamine;

N-[3-(2,6-dichloro-phenyl)-2,- 5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N-(1-ethyl-piperidin-3-yl)-ethane-1,2-diamine;

N-(1benzyl-pyrrolidin-3-yl)-N'-[3-(2,6-dichloro-phenyl)-2,5-dimethyl-pyrazolo [1,5a]pyrimidin-7-yl]-ethane-1,2-diamine;

N-[3-(2,6-dichloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-pyrimidin-2-yl-ethane-1,2-diamine;

N-(1-benzylpiperidin-4-yl)-N'-[3 -(2,4-dichloro-6-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-ethane-1,2-diamine;

N-(1-benzyl-piperidin-4-yl)-N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-ethane-1,2-diamine;

N-[3(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1'-methyl-piperidin-4-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5 dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-piperidin-4-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl] -N'-(1-isopropyl-piperidin-4-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-ethane-1,2- diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]- pyrimidin-7-yl]-N'-(1-ethyl-piperidin-3-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazo to [1,5-a] pyrimidin-7-yl]-N'-piperidin-4-yl-ethanel, 2-diamine;

N^2(1-Benzyl-piperidin-4-yl)-N'-[3-(2,6-dichloro-phenyl) -2,5-dimethyl-pyrazolo[1,5-ajpyrimidin-7-yl]-propane-1,2-diamine;

N-[3-(2,6-Dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-pyridin-3-ylmethyl-piperidin -4-yl)-ethane-1,2-diamine;

N-[3-(2,6-Dichloro-4-methoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin- -7-yl]-N'-(1-pyridin-4-ylmethyl-piperidin4-yl)-ethane-1,2-diamine;

3,5-Dichloro-4-12,5-dimethyl-7-[2-(1-phenyl-pyrrolidin -3-ylamino)-ethylamino]-pyrazolo[1 ,5-a]pyrimidin-3-yl]-phenol;

N-[3-(2,6-2,5dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-(1-pyridin -2-ylmethyl-piperidin-4-yl)-ethane-1,2-diamine;

3,5-dichloro-4-(2,5-dimethyl-7-[2-(1-pyrimidin-2-yl-piperidin-4-ylamino)--ethylamino]-pyrazolo [1,5-a]pyrimidin-3-yl }-benzonitrile;

N-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5 a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine- ;

N-[3-(2,6dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N-(1-benzyl-piperidin-4-yl)-N'-[3(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimet- hyl-pyrazolo 1,5-a]pyrimidin-7-yl]-ethane-1,2-diamine;

N-[3-(2,6-dichloro-phenyl)-5-ethyl-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl-]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-phenyl)-5isopropyl-2-methyl-pyrazoto [1,5-a]pyrimidin-7-yl]-N-(1 -pyrimidin-2-yl-piperidin-4-yl)ethane-1,2-diamine;

N-[3-(2,4-dichloro-phenyl)-5-isopropyl-2-methyl-pyrazolo [1,5a]pyrimidin-7-yl]-N'-(1 -pyrimidin -2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N'-[3-(2,6-dichloro-4-ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]p- yrimidin-7-yl]-N^2-(1 -pyrimidin -2-yl-piperidin-4-yl)-propane-1,2-diamine;

N'-[3-(2,6-dichloro-4-methoxy-phenyl)-5isopropyl-2-methyl-pyrazoto [1,5-a]pyrimidin-7-yl]-N^2-(1-pyrimidin-2-yl-piperidin-4-yl)propane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-5-ethyl-2-methylpyrazoto [1,5-a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N'-[3-(2,6-dichloro-4-methoxy-phenyl)-2-methyl-5-propyl-pyrazolo[1,- 5-a]pyrimidin-7-yl]-N^2-(1-pyrimidin-2-yl-piperidin-4-yl)-propane-1,2-diamine;

N'-[3-(2,6-dichloro-4methoxy-phenyl)-5-ethyl-2-methyl-pyrazoto [1,5-a]pyrimidin-7-yl]-N^2-(1-pyrimidin-2-ylpiperidin-4-yl)-propane-1,2-diamine;

N-[3-(2,6-dichloro-phenyl)-2-methyl-5-propylpyrazoto [1,5-a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N'-[3-(2,6-dichloro-phenyl)-2-methyl-5-propyl-pyrazolo[1,5-a]pyrimid- in-7-yl]-N^2-(1-pyrimidin-2-yl-piperidin-4-yl)-propane-1,2-diamine;

N'-[3-(2,6-dichloro-phenyl)-5-ethyl 2-methyl-pyrazolo[-1,5-a]pyrimidin-7-yl]-N^2-(1-pyrimidin-2-yl-piperidin-4-yl)-propanel,2-diamine;

N-[5-ethyl-2-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N'-[5-ethyl-2-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-N^2-(1-pyrimidin-2-yl-piperidin -4-yl)-propane-1,2-diamine;

N-[3-(2,6dichloro-4-ethynyl-phenyl)-2,5-dimethylpyrazolo [1,5-a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N-[2-methyl-5 -propyl-3 -(2,4,6-trimethyl-phenyl)-pyrazo to [1,5-a]pyrimidin-7-yl]-N'-(1 pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N'-[3-(2,6-Dimethyl-phenyl)-5-ethyl-2-methyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-(1 -pyrimidin-2-yl-piperidin-4-yl)-propane-1,2-diamine;

N-[3 -(2,6-dimethyl-phenyl) -2-methyl-5-propyl-pyrazolo [1,5 -a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane -1,2-diamine;

N'-[3-(2,6-Dimethyl-phenyl)-2-methyl-5-propyl-pyrazolo[1,5-- a]pyrimidin-7-yl]-NZ-(1-pyrimidin-2-yl-piperidin-4-yl)-propane-1,2-diamine;

N'-[3-(2,6dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-N- .sup.2-(1-pyrimidin-2-ylpiperidin-4-yl)-propane-1,2-diamine;

N-[3-(2,4-dimethyl-phenyl)-5-ethyl-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl-]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine;

N-[3-(2,4-dimethyl-phenyl)-2-methyl-5-propyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(1-pyrimidin-2-yl-piperidin-4-yl)-ethane-1,2-diamine; and

1-[4-(1{[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-ylamino]-methyl] -propylamino)piperidin-1-yl]-ethanone.

41. (original) A compound of claim 37 where the structure is selected from the group consisting of

N-[2,5 -dimethyl-3-(2,4,6-trimethylphenyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxy-phenyl)-ethyl]-ethane-1,2diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-[2-(4-methoxy-phenyl)-ethyl]-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-[2-(3-ethoxy-4-methoxy-phenyl)-ethyl]-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-[2-(4-ethoxy-3-methoxy-phenyl)-ethyl]ethane-1,2-diamine;

N-[3-(2- ,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,a]pyrimid in-7-yl]-N'-(1,2,3,4-tetrahydro-naphthalen-2-yl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-(2-pyridin-2-yl-ethyl)-ethane-1,2-diamine;

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidi- n-7-yl]-N'-(2-pyridin-3-yl-ethyl)-ethane-1,2-diamine; and

N-[3-(2,6-dichloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo [1,5-a]pyrimidin-7-yl]-N'-(2-pyridin4-yl-ethyl)-ethane-1,2-diamine.

42-44. (canceled)

45. (original) A pharmaceutical composition which comprises a therapeutically effective amount of compound of claim 24 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.

46. (original) A pharmaceutical composition for the treatment of obesity which comprises a therapeutically effective amount of compound of claim 24 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.

47-50. (canceled)

51. (original) A pharmaceutical composition according to claim 24 for the treatment of disorders or disease states caused by eating disorders, of obesity, bulimia nervosa, diabetes, dislipidemia, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression, anxiety, cerebral hemorrhage, shock, congestive heart failure, nasal congestion or diarrhea.

52-79. (canceled)